Videos

"This work isn't for one; it is certainly for all,” says Efe C. Ghanney Simons, MD.

“Rather than asking the staff to have a stiff upper lip and cope, we instead tried to focus on uncovering systemic processes that were ripe for change,” says Loren Jean Smith.

“The quality of life overall between the 2 approaches was very similar,” says Peter Chang, MD, PhD.

Ernest Sussman, MD, FACS, explains why all urologists must also be risk managers.

“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.

“I think the key [is to not] get rid of financial incentives. I don't think that's possible. [Rather, we should] align financial incentives [so] that [we] can promote what is best for patients,” says Lillian Y. Lai, MD.

Kyle Wood, MD, reviews current therapies and strategies for the management of enteric hyperoxaluria.

“This type of collaboration [between SEER and GPS assay] is a really nice illustration of the types of projects that we should be undertaking in the future,” says Scarlett Gomez, MD, PhD.

“[Rezum] does give men another option, and so I think that's…really what we're focusing on here: giving the option to avoid general anesthesia and to avoid a bigger surgery,” says Michael A. Palese, MD.

“The goal of this research endeavor was to really set forth the background information that would guide the creation of targeted interventions,” says Efe C. Ghanney Simons, MD.

Welcome to the first installment of Uranimals, a video series featuring urologists and their pets brought to you by Urology Times. From a dog model to a whole farm of animals, the inaugural episode has an amazing lineup.

“We're getting close, and we hope to have things concluding here soon and then to be able to offer some of these technologies on a on a wider scale,” says Mathew D. Sorensen, MD, MS, FACS.

“This is a successfully completed phase 3 trial in regenerative medicine in our field, and there's demonstrated safety and efficacy for women who have failed previous surgery, a very difficult group of patients for all of us,” says Michael B. Chancellor, MD.

In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it could change the future of prostate cancer testing.

“It works on the bladder [and] it relieves the symptoms of people who have overactive bladder, but it doesn't do any adverse things to blood pressure or heart rate.” says Michael A. Weber, MD.

“I’m looking forward to comparisons of minimally invasive surgery versus medical therapy, that is, at this point, untapped. It's something which we think we have insight into, but we really don't have good data,” says Kevin T. McVary, MD.

“The activity that we saw with the combination was very promising and…it justifies additional clinical trials to determine whether or not this could have a place in terms of our standard treatment options for patients,” says Michael Schweizer, MD.

“Our data shows that in newly diagnosed men with prostate cancer, yoga improved quality of life [as well as] some immune markers, and [lowered] inflammation,” says Dharam Kaushik, MD.

“We're increasingly seeing the addition of molecular and genetic tests to guide us in terms of the cancer treatment that we provide our patients,” says Scarlett Gomez, MD, PhD.

“We were able to show that there was a very…clinically significant decrease in the rate of UTIs in the vaccinated group, preventing UTIs in almost 60% of vaccinated patients,” says J. Curtis Nickel, MD.

“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.

“Figuring out a good, comfortable way to bring that [ED] conversation up…will really pay dividends in other parts of the health care system. It will also allow more people to appropriately get funneled to urology to better address it,” says Denise Asafu-Adjei, MD, MPH.

“[BPH treatment] has to be individualized to the motivations of the patient, and also what I call his "phenotype.” How big is his prostate? How bad is this problem? And what is his tolerance for side effects?” says Kevin T. McVary, MD.

"These data are growing rapidly, and awareness of where we stand right now and the potential that could change as well in the future with new data is important for the practicing urologist,” says Peter N. Schlegel, MD, FACS.

“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.

“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.

“More research needs to be done, but I think this is something that gets the conversation started,” says Tony Chen, MD.

“The take-home message for all practicing urologists should be that if you have an nmCRPC patient, don't wait for them to develop mCRPC based on conventional imaging…We have 3 really efficacious level 1 evidence studies that have demonstrated the value for starting any of these 3 drugs,” says Neal D. Shore, MD.

“In those resistance cells, there is a lot of senescence occurring there, so that provides some potential target…which can be used to improve those PARP inhibitor therapies,” says Allen C. Gao, MD, PhD.

"In the clinic, I think the biggest benefit, at least immediately, is that by asking and trying to figure out what a patient's tobacco use history is, you can help with quitting,” says Richard Matulewicz, MD, MS.